BRK-B vs JRI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
The deterministic health profile for JRI is critically weak, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental deterioration. While the fund offers an attractive dividend yield of 12.51%, the 90% payout ratio suggests limited sustainability and potential capital erosion. The current price of $12.81 trades at a premium to the growth-based intrinsic value of $12.32, and the technical trend is completely bearish (0/100). Overall, the combination of poor financial health scores and negative price momentum outweighs the high yield.
Compare Another Pair
Related Comparisons
BRK-B vs JRI: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Nuveen Real Asset Income and Growth Fund (JRI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.